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or more than 50 years, electroconvulsive ther-
apy (ECT) has been the only nonpharmacological,
somatic treatment of psychiatric disorders in wide-
spread clinical use. Other modalities, such as insulin
coma therapy, were used for varying periods, but no
longer have any place in clinical psychiatry.This situa-
tion is now changing. Brain stimulation techniques are
rapidly becoming a highly promising novel avenue for
treatment of psychiatric disorders in general,and major
depression in particular. Research in this field is at a
very important juncture, and there are signs that the
first two decades of the current millennium could well
be the decades of brain stimulation in psychiatry.
Several different approaches are under study. Some
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Until recently, a review of nonpharmacological, somatic treatments of psychiatric disorders would have included only
electroconvulsive therapy (ECT). This situation is now changing very substantially. Although ECT remains the only
modality in widespread clinical use, several new techniques are under investigation. Their principal indication in the
psychiatric context is the treatment of major depression, but other applications are also being studied. All the novel
treatments involve brain stimulation, which is achieved by different technological methods. The treatment closest
to the threshold of clinical acceptability is transcranial magnetic stimulation (TMS). Although TMS is safe and relatively
easy to administer, its efficacy has still to be definitively established. Other modalities, at various stages of research
development, include magnetic seizure therapy (MST), deep brain stimulation (DBS), and vagus nerve stimulation
(VNS). We briefly review the development and technical aspects of these treatments, their potential role in the treat-
ment of major depression, adverse effects, and putative mechanism of action. As the only one of these treatment
modalities that is in widespread clinical use, more extended consideration is given to ECT. Although more than half a
century has elapsed since ECT was first introduced, it remains the most effective treatment for major depression, with
efficacy in patients refractory to antidepressant drugs and an acceptable safety profile. Although they hold consider-
able promise, the novel brain stimulation techniques reviewed here will be need to be further developed before they
achieve clinical acceptability.  
© 2006, LLS SAS Dialogues Clin Neurosci. 2006;8:241-258.while others are still at a very limited stage of applica-
tion in the research context only.
In this review,we will consider several novel brain stim-
ulation techniques for the treatment of depression:tran-
scranial magnetic stimulation (TMS),magnetic seizure
therapy (MST),deep brain stimulation (DBS),and vagus
nerve stimulation (VNS).A comprehensive evaluation
of each modality is not possible in this context.We will
provide an overview of key aspects of each treatment
such as its development,technique,application in major
depression,adverse effects,and putative mechanism(s)
of action.The novel brain stimulation modalities will be
discussed on the background of a wider consideration of
ECT,which is used extensively and has been the focus of
intensive basic and clinical research for several decades.
Electroconvulsive therapy 
Development of ECT
The production of epileptiform convulsions as a treat-
ment for psychiatric illness was introduced in 1934 by the
Hungarian psychiatrist,Laszlo Meduna.
1The first treat-
ments were drug-induced convulsions.
2A few years later,
electrical seizure induction was introduced by Cerletti
and Bini in Rome.
3,4The introduction of antidepressant
drugs during the 1950s and 1960s reduced the use of ECT
as a first-line therapy for depression.Nevertheless,ECT
is still the treatment of choice in pharmacotherapy-resis-
tant cases. Although ECT is considered effective and
safe,it continues to be regarded with suspicion by much
of the public and the medical profession. Hollywood
films such as The Snakepit (1948) and One Flew Over the
Cuckoo's Nest (1975) set an antipsychiatric and anti-ECT
tone that has never completely abated.
5 Unmodified
ECT was indeed associated with serious complications
such as extremity fractures and compressive spinal frac-
tures. However, for more than 50 years ECT has been
administered under general anesthesia with neuromus-
cular relaxants, and this has eliminated these serious
complications.
6 Interestingly,the fear of permanent brain
damage caused by ECT was recently placed in a differ-
ent perspective by reports that ECT might actually
increase new neuron growth (neurogenesis) in the hip-
pocampus.
7
In order to minimize short- and longer-term memory
deficits associated with ECT,major research efforts have
been invested in trying to limit the stimulus path and to
adapt the stimulus intensity to the seizure threshold of
the individual patient.
8There are two main modalities of
ECT,differentiated by electrode placement:bilateral and
unilateral ECT.In bilateral ECT the electrical stimulus
traverses both cerebral hemispheres,while in unilateral
ECT only the nondominant cerebral hemisphere is stim-
ulated.In both cases,effective treatment requires that a
generalized seizure be elicited.Although unilateral ECT
results in fewer cognitive adverse effects,its efficacy rel-
ative to bilateral ECT was a source of controversy for
many years.
9 Recently, Sackeim and colleagues found
that high-dosage unilateral ECT (electrical dosage 500%
above seizure threshold) and moderately suprathreshold
bilateral ECT (electrical dosage 150% above seizure
threshold,) are equivalent in response rate.
10 Importantly,
high-dose unilateral ECT is not associated with increased
cognitive adverse effects.These findings underscore an
important basic concept in ECT: although the seizure
may seem to be an all-or-none event,not every general-
ized seizure has antidepressant properties. Stimulus
intensity relative to threshold is a major factor in the effi-
cacy of the therapy.
11,12
Technique of ECT administration
Pretreatment evaluation includes complete medical his-
tory,physical,neurological,and preanesthesia examina-
tions,and relevant laboratory tests.Patients' concurrent
medications should be noted,since they might affect the
seizure threshold or interact with other medications used
during ECT (Table I).Pretreatment preparations include
6- to 12-hour fasting,removal of dentures or other for-
eign objects from the patient's mouth,insertion of a bite
block into the mouth,and preoxygenation (100% O2 at
a rate of 5 L/min).
Anesthetic agents should induce rapid unconsciousness
and recovery and minimally affect hemodynamic para-
meters or seizure threshold.
18The most commonly used
anesthetic is methohexital (0.75 to 1.0 mg/kg),due to its
rapid onset,short duration of action,minimal anticon-




Selected abbreviations and acronyms
DBS deep brain stimulation
ECT electroconvulsive therapy
MST magnetic seizure therapy
TMS transcranial magnetic stimulation
VNS vagus nerve stimulationinclude thiopental, propofol, and etomidate.A muscle
relaxant agent is administered 1 to 2 minutes after the
anesthetic agent.Muscle relaxation eliminates injuries
resulting from motor activity during the treatment,and
is of particular importance in patients who are at high
risk for fractures or disk herniation.Succinylcholine,a
short-acting depolarizing agent (0.5 to 1.0 mg/kg),is used
in most patients.Before the muscle relaxant is adminis-
tered,a blood pressure cuff is inflated above the systolic
blood pressure at one ankle,to allow observation of the
motor seizure.A peripherally acting anticholinergic such
as glycopyrrolate may used to increase heart rate before
treatment,especially if the patient is bradycardic.
ECT is administered using two electrodes,located bilat-
erally or unilaterally,as illustrated in Figure 1.The elec-
trical stimulus is a brief pulse waveform (bidirectional
rectangular pulse).The intensity of the ECT stimulus is
assessed in terms of the total delivered charge.This total
charge (Q,measured using units of millicoulombs) can
be defined as:
Q = (I/1000) * PW * 2F * D
where I is current (milliamperes),PW is pulse width (mil-
liseconds),F is frequency (hertz,cycle per second) and D
is duration (seconds).The standard pulse width used in
ECT is 1 millisecond or greater. Recently, it has been
found that an ultrabrief stimulus,using 0.3 millisecond
pulse width,requires less energy to produce a general-
ized seizure.This may be related to the fact that neuronal
depolarization is 0.3 to 1.0 milliseconds,and long pulse
width may result in excess stimulation after neurons have
fired and are in a refractory or relative refractory phase.
Although the amnesia and cognitive side effects follow-
ing ECT are reduced with ultrabrief stimulation, data
regarding its efficacy relative to the traditional stimulus
are still insufficient.
The electrical path of the ECT stimulus includes the ECT
output device, stimulus electrodes, scalp, skull, cere-
brospinal fluid, and brain tissue. The most variable
impediment is the patient impedance (mostly scalp and
skull), measured in ohms. Energy is another unit that
assesses the intensity of the total electrical stimulus.It is
dependent on the impedance during stimulation,and can
be calculated as 
U = (Q/1000) * (I/1000) * R
where Q is charge (millicoulombs), I is current (mil-
liamperes),and R is resistance (ohms).
Seizure threshold,defined as the minimal stimulus inten-
sity necessary to produce a seizure,differs up to 40-fold
among patients (Figure 2).For example,seizure thresh-
old is higher in men than in women and is higher in older
than younger adults.Seizure threshold is also altered by
mechanical factors that impede the path of the stimulus
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Figure 1. Electrode placement in ECT. In bilateral ECT, bifrontotempo-
ral electrode placement is used: the electrodes are placed 5
cm above the midpoint of the distance between the auditory
meatus and the external canthus. In unilateral ECT, the d'Elia
positioning is used: one electrode is placed at the standard
frontotemporal position, and the other electrode is placed
near the vertex (3 cm down from the midpoint of a line join-
ing the two auditory meati and the sagittal midline of the
skull). ECT, electroconvulsive therapy.
Table I. Drug coadministration with electroconvulsive therapy.
Drug Concomitant administration with ECT
Lithium
13 Discontinue before ECT. Lithium decreases the intracellular production of 
acetylcholine, may prolong the action of succinylcholine, and may prolong 
seizure duration
Tricyclic antidepressant, monoamine oxidase inhibitors  Safe
selective serotonin reuptake inhibitors
14,15
Bupropion
16 Controversial. Bupropion may cause prolonged seizure




18 Controversial, might induce late seizuresand increase resistance.Seizure threshold may change in
the same patient during the ECT course, and tends to
increase,as shown in Figure 3.
Optimal stimulus intensity during ECT is important
because excessive electrical stimulation increases cog-
nitive deficits.On the other hand,insufficient electrical
stimulation,barely above the seizure threshold,reduces
efficacy.In a study that compared bilateral and right uni-
lateral ECT at different stimulus intensities,Sackeim and
colleagues concluded that the optimal electrical dosage
is 2.5 times the seizure threshold for bilateral ECT and 4
to 6 times the seizure threshold for unilateral ECT.
10 For
ultrabrief stimulation (pulse width 0.3 millisecond),the
electrical dosage might be higher.
Determining the stimulus energy requires a method to
estimate the patient's seizure threshold in the first treat-
ment session.Empirical titration involves administration
of subconvulsive intensities in the first treatment and
finding the stimulus energy that produces a seizure.In
subsequent sessions,a fixed stimulus above the seizure
threshold is administered.In every treatment session,up
to three trials of stimulus may be conducted. Using
empirical titration permits accurate determination of the
seizure threshold.Another method to estimate seizure
threshold,the preselected dosage method,involves use
of known predictors of seizure threshold such as elec-
trode placement,age,and gender.Based on these crite-
ria,a suprathreshold dose is preselected and given at the
first and subsequent treatments,unless severe cognitive
side effects occur.This approach eliminates the need for
subconvulsive stimulations in establishing seizure thresh-
old,but is less accurate than the titration method.
The motor seizure consists of two phases.The tonic phase
lasts 10 to 20 seconds and involves contraction of the jaw
and facial muscles,plantar extension,and high-frequency
sharp EEG activity.The second phase,the clonic phase,
involves rhythmic contractions and bursts of polyspike
EEG activity which persist for a few seconds after the
clonic movements stop.A seizure is effective if it lasts at
least 20 to 25 seconds.Prolonged seizures can be termi-
nated with intravenous benzodiazepines.
Clinical research
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Figure 2. Initial seizure threshold in milliampere seconds (millicoulombs)
as determined by a titration technique at the first treatment
of a bilateral ECT course.



























75 76 120 126 134 168 176 235 236 313 252 327 428
Figure 3. Increase in seizure threshold measured by titration at treat-
ments 1, 8, and 12 (A) and decrease in seizure duration mea-
sured clinically in a cuffed limb (B) in patients treated with
bilateral ECT.
















































































8 12In the United States,ECT is usually administered three
times weekly.In other parts of the world,twice-weekly
administration is more common.Twice-weekly adminis-
tration has been shown experimentally to be an optimum
schedule for bilateral ECT,considering maximal antide-
pressant effect and minimal cognitive impairment.
21,22 If
clinical indications require a more rapid antidepressant
effect, three times weekly administration might be
used.
21,22The number of treatments during an ECT course
is usually 8 to 12; the treatment is terminated when a
plateau of improvement is reached, usually when the
patient does not continue to improve after two consecu-
tive treatments.
ECT in the treatment of major depression
It is well established that ECT is an effective treatment for
major depression, superior to placebo, simulated ECT
(anesthesia only),and antidepressant medication.
23-26 Of
patients with major depression who receive ECT as a first-
line treatment, 80% to 90% show significant improve-
ment. Currently, most patients with major depression
treated with ECT have failed two or more courses of anti-
depressant medication. ECT is effective in over half of
these patients.
10,27 ECT is indicated in patients intolerant of
antidepressant medication and those with medical illnesses
that contraindicate the use of antidepressants.ECT may
be considered as a first-line treatment in severe depression
or depression with specific features,such as psychosis,
28,29
catatonia,
30 melancholia (mainly food refusal leading to
nutritional deficit),
31 or suicidality.
32-34 ECT is also effective
and safe in the elderly,among whom depressions tend to
be persistent,and the patients suffer from other systemic
disorders and consume many medications.
35 During preg-
nancy,ECT is usually only considered if the fetus is at risk
from the unstable psychiatric condition of the mother.
36
ECT may also be considered for patients who have previ-
ously shown a positive response to ECT or patients who
prefer this treatment.
Although it is difficult to predict response to ECT,there
are factors associated with poorer response to ECT such
as refractoriness to antidepressant medication,chronicity
of the depression,and personality disorders.
37,38 Relapse
rate during the 6 months following ECT exceeds 50%,
39,40
with the bulk of the relapses occurring within 1 month of
termination of the treatment course.Continuation therapy
markedly reduces the relapse rate.
41 Following ECT,con-
tinuation therapy might include pharmacotherapy,
42 main-
tenance ECT,
43 or a combination of maintenance ECT and
an antidepressant agent.In a recent multicenter random-
ized study,the combination of lithium and nortriptyline
was shown to reduce the relapse rate by 50%.
44
Adverse effects
The most important adverse effect of ECT is memory
impairment.Concern about memory loss is intensified
for the patient and family by the transient confusion that
occurs after each seizure.High-dose unilateral ECT pro-
duces less severe and persistent cognitive adverse effects
than bilateral ECT.
10 In the postictal period, bilateral
ECT causes more prolonged disorientation and more
severe retrograde amnesia than unilateral ECT. One
week and 2 months after the course, bilateral ECT is
associated with greater anterograde and retrograde
memory deficits. During the first 2 months after ECT,
bilateral ECT is associated with greater retrograde
amnesia than unilateral ECT. Most patients return to
their cognitive baselines 6 months after ECT,although a
few patients complain of permanent memory loss.
Other side effects of ECT include headache, nausea,
vomiting,myalgia,back pain,or damage to teeth if appro-
priate precautions are not taken.
Patients with increased intracranial pressure (due to an
intracranial mass or obstruction of cerebrospinal fluid
flow) are at risk for brain edema or herniation after ECT.
Most clinicians regard increased intracranial pressure as
an absolute contraindication to ECT.In these patients,
pretreatment with steroid,diuretic,or antihypertensive
agents can reduce the risk. Several coexisting disease
processes warrant special attention due to their potential
for complications in the context of ECT.The cardiovas-
cular risk of ECT is a product of the stress of ECT itself,
the severity and stability of coronary artery disease,and
hemodynamic changes after the ECT (parasympathetic
and then sympathetic response).
45 Identifying and con-
trolling risk factors such as hypertension, arrhythmias
(especially tachycardia),angina,congestive heart failure,
and diabetes mellitus can minimize the risk of post-ECT
ischemia.
18 Controlling hypertension is especially impor-
tant since during ECT,systemic blood pressure increases
acutely.
The estimated mortality rate with ECT is between two and
ten per 100 000,about 0.002% per treatment,and 0.01%
for each patient.
46,47This mortality rate is equivalent to the
mortality rate with general anesthesia (1:50,000).
48
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The mechanism of action of ECT has intrigued psychia-
trists and neuroscientists since the treatment was first
introduced.Laszlo Meduna,
1 the inventor of convulsive
therapy,suggested that chemically induced seizures were
effective in the treatment of schizophrenia by “changing
the chemical composition of the brain.”The first com-
prehensive book on ECT mechanisms was published in
1974.
49 A second book on the topic appeared a decade
later.
50 Several dedicated review papers and book chap-
ters have been published since.In the course of ECT an
electrical current traverses brain tissue and a grand mal
seizure ensues;it is inevitable that events such as these
will have major physiological consequences.As noted by
Seymour Kety,
51 ECT “..involves massive discharge over
wide areas of the brain,activation of the peripheral auto-
nomic nervous system,release of the secretion of many
endocrine glands..”and as a result “..the difficulty lies not
in demonstrating such changes but in differentiating..
which of the changes may be related to the important
antidepressive and amnestic effects and which are quite
irrelevant to these.”
An important implication of Kety’s highly relevant
observation is that research into the mechanism of action
of ECT should take into account clinical aspects of the
treatment that have a potentially important impact in the
research context. The first consideration is that long-
standing changes induced by repeated administrations of
electroconvulsive shock (ECS) are much more likely to
be relevant to the therapeutic mechanism of ECT than
transient effects of a single ECS.The therapeutic spec-
trum of ECT is another highly relevant consideration.In
addition to its antidepressant properties,ECT has anti-
manic,antipsychotic,anticatatonic,antiepileptic,and anti-
convulsant effects,and is used clinically for all these indi-
cations.It is highly implausible that a single mechanism
of action will explain all these varied,and in some cases
opposite,clinical effects.In considering the antidepres-
sant mechanism of ECT,it is also important to note that
ECT is substantially more effective than antidepressants;
more than 50% of patients who have not responded to
at least two adequate trials of antidepressant medication
will respond to ECT. Furthermore, ECT is effective in
patients with psychotic depression whereas antidepres-
sant drugs are not, unless administered in conjunction
with an antipsychotic. All these observations provide
some explanation of why a definitive understanding of
the mechanism of action of ECT has proved so elusive in
spite of the enormous efforts that have been invested.
A comprehensive analysis of the various theories of ECT
action in depression and the evidence that has been gath-
ered in support of them is beyond the scope of this paper.
The overall focus of recent work may be summarized
under a few general headings.Recent intriguing findings
regarding the effect of ECT on synaptic plasticity and
neurogenesis will be considered more extensively.
One important research direction has been the effect of
ECT on neurotransmitters,receptors,and postreceptor
signaling mechanisms in the brain,particularly those that
are implicated in the mechanism of action of antidepres-
sant drugs.The emphasis has been primarily on seroton-
ergic, noradrenergic, and dopaminergic systems with
some consideration of γ-aminobutyric acid (GABA)-
ergic and more recently glutamatergic mechanisms.
52-55
Electrophysiological studies suggest that an important
effect of ECS on brain serotonergic systems in rodent
brain is sensitization of postsynaptic serotonin (5-HT)1A
receptors and a consequent increase in serotonergic
transmission.
56 This may be reflected in patients in
increased responsiveness to serotonergically mediated
neuroendocrine challenges.
57 There is great variability,
however,in the overall effect of ECS on serotonin recep-
tors as well as regional differences.
54,58 In the noradren-
ergic system, the density of postsynaptic β-adrenergic
receptors is reduced by ECS, while autoreceptors that
modulate noradrenaline release are inhibited.
52,53The net
effect may be an increase in postsynaptic signal trans-
duction.
55,58 Dopaminergic function is increased postsy-
naptically,a finding that is consistent with the antiparkin-
sonian effects of ECT but difficult to reconcile with its
antipsychotic action.
59
A second major research direction may be termed neu-
rophysiological.It encompasses the extensive work that
has been done to evaluate the effects of ECT on brain
electrical activity and cerebral blood flow (CBF) and
metabolism. There is considerable evidence that
depressed patients have reduced CBF and metabolism
compared with normal subjects,although in some brain
areas it may be increased.
60,61 Some studies suggest that
reduced CBF in depression is reversed by ECT,but oth-
ers report a further reduction.
62,63 Reduced brain function
as a consequence of ECT is consistent with the hypothe-
sis that recruitment of endogenous inhibitory processes




246A third research direction takes as its starting point the
substantial endocrine effects of ECT and suggests that
these effects are implicated in the therapeutic mechanism
of the treatment.
64 Plasma prolactin levels are acutely
increased by ECT.
65,66This is a consistent finding,but it
has been difficult to explain how it might be related to
the therapeutic action of ECT.Another focus has been
on the effect of ECT on thyrotropin-releasing hormone
(TRH) and TRH-receptor function.
67
More recently there has been a great deal of emphasis on
the effect of ECS on synaptic plasticity and neurogene-
sis.Adult neurogenesis,the lifelong addition of new neu-
rons,was first documented in rat hippocampus.
68 It is now
well established that neurogenesis occurs in several dif-
ferent species,including humans.
69The newly generated
cells mature into functional neurons.
70 Neurogenesis is
regulated by many factors.Upregulation of neurogene-
sis occurs in response to enriched environment,
71 exer-
cise,
72,73 and learning. Downregulation of neurogenesis
occurs in response to aging
74,75 and stress (psychological
or environmental).
76 It is well established that the volume
of hippocampus is decreased in patients suffering from
depression.
71,72 Repeated stress causes atrophy of den-
drites in the CA3 region, and both acute and chronic
stress suppresses neurogenesis of rat dentate gyrus gran-
ule neurons.The hippocampus is an especially plastic and
vulnerable region, and a target of stress hormones
(gonadal,thyroid,and adrenal hormones).This cell loss
might explain the reduction in hippocampal volume
observed in depression.Decreased neurogenesis might
also explain some of the symptoms of depression,such as
cognitive abnormalities and loss of inhibitory control of
the hypothalamic-pituitary-adrenal (HPA) axis.Recently,
it has been demonstrated that chronic administration of
several classes of antidepressant treatment,such as sero-
tonin or norepinephrine selective reuptake inhibitors,
monoamine oxidase inhibitors,lithium,and ECS upreg-
ulates neurogenesis in adult rodent hippocampus.
79-84 ECS
influences some molecular markers of neuronal plastic-
ity;for example,ECS decreases the level of phosphory-
lated heavy and light neurofilament subunit (NF-H and
NF-L),that may be part of the cytoskeletal remodeling.
85
ECS also influences several trophic factors that are
related to neurogenesis,for example,brain-derived neu-
rotrophic factor (BDNF),which increases the synaptic
strength,survival,and growth of adult neurons.ECS pro-
longs the expression of BDNF and its receptor,trkB,and
blocks the downregulation of BDNF mRNA in the hip-
pocampus in response to restraint stress.
86 ECS has been
demonstrated to change gene transcription in rat hip-
pocampus,including genes that are related to neurogen-
esis,such as BDNF-MAP kinase-cAMP-cAMP response





From the late 19th century many attempts were made to
induce neural activity by magnetic stimulation until
Barker and colleagues showed 20 years ago that mag-
netic stimulation of the human motor cortex produces
depolarization of cortical areas.
88Transcranial magnetic
stimulation has been found to be a noninvasive, easily
tolerated method of probing cortical brain function.
During the last decade,many studies have indicated that
TMS has antidepressant properties,
89,90 but its clinical
effect is not yet clear.
Technique of TMS
In TMS,a magnetic field is generated by an electric cur-
rent,and this magnetic field induces an electric current
within the brain.The patient is awake,and sessions last
20 to 60 min.The treatment lasts a few weeks,since mul-
tiple sessions are indicated.An alternating electric cur-
rent passes through a metal coil that is placed on the
patient's scalp.
91The electric current induces an alternat-
ing magnetic field, perpendicular in orientation to the
current flow.The magnetic field passes through the scalp
and skull without impedance and causes depolarization
of cortical brain cells.The electrical current is parallel and
opposite in direction to the electrical current in the coil.
The stimulated brain area depends on two major factors:
the coil design
92 and the coil orientation.
93The magnetic
field depolarizes cells to a depth of 2 cm below the scalp,
near the gray-white junction of the nervous tissue.
94
Single-pulse TMS is generated by a single magnetic pulse,
while repetitive TMS (rTMS) is generated by magnetic
pulses given in a regular frequency.The stimulation fre-
quency might be fast (more than 1 Hz) or slow (1 Hz and
less).The two frequencies of stimulation have opposite
effects on brain excitability and metabolism.Fast rTMS
and slow rTMS have been associated with increased and
decreased cortical excitability and regional blood flow,




95,96 Slow frequency stimulation has a lower
risk of inducing seizures.
97The intensity of the magnetic
pulse is measured relative to the motor threshold,which
is the lowest intensity of stimulation that produces spe-
cific muscle contraction in at least 5 of 10 trials.
98
Most studies uses fast rTMS over the left hemisphere and
slow rTMS over the right hemisphere.Using fast rTMS
over the left dorsolateral prefrontal cortex is based on
the finding that functional activity in this area is low in
patients suffering from major depression
99 and assumes
that fast rTMS will enhance activity in this brain area.
Use of slow rTMS over the right dorsolateral prefrontal
cortex is aimed at reducing overactivity in this brain area
and thus resolving a suspected hemispheric imbalance.
100
TMS in the treatment of major depression
Administering rTMS to healthy individuals has not been
shown to induce significant mood changes,
101 although
left prefrontal rTMS is associated with transient
decreased happiness and right prefrontal rTMS with
transient decreased sadness.
102,103 Compared with sham
administration,slow and fast rTMS have been shown to
have some antidepressant properties.
104-109 However,ana-
lyzing these studies is difficult due to the different tech-
niques used such as different frequencies,coil design,and
positions.
A systematic review by Burt et al evaluated the antide-
pressant effect of TMS.
110 A meta-analysis of open and
uncontrolled studies showed an antidepressant effect,but
the clinical significance of this effect was uncertain,since
most patients did not meet standard criteria for clinical
response or remission. A meta-analysis of controlled
studies showed that rTMS has superior antidepressant
properties compared with sham administration (Figure
4). However, similarly to the uncontrolled studies, the
therapeutic effect was of doubtful clinical significance
due to modest average effect and small average differ-
ence in improvement between active and sham condi-
tions.A subsequent systematic review and meta-analysis
included 14 trials.
111 Pooled analysis using the Hamilton
Rating Scale for Depression showed an effect in favor of
rTMS compared with sham after 2 weeks of treatment,
but this was not significant at follow-up 2 weeks after the
intervention period.The conclusion of this analysis was
that “current trials are of low quality and provide insuf-
ficient evidence to support the use of rTMS in the treat-
ment of depression.”This conclusion is shared by two
other reviews
112,113 but not by another meta-analysis of
randomized sham-controlled trials of left prefrontal
rTMS that found an “acute antidepressant treatment
with statistically significant effect sizes and measurable
clinical improvement.”
114 It is clear that further controlled
studies using standardized methodology are needed in
order to establish the place of rTMS in the treatment of
major depression.
A few studies have compared the antidepressant effect
of rTMS and ECT.
115-118 These suggest that the antide-
pressant effect of rTMS is similar or slightly inferior to
the antidepressant effect of ECT;however,in these stud-
ies the average improvement with ECT was unusually
low.Comparing psychotic and nonpsychotic patients,it
has been reported that rTMS and ECT have a similar
Figure 4. Meta-analysis of controlled trials of TMS. Figure shows effect
size (d) and 95% confidence intervals for randomized, con-
trolled studies of TMS and rTMS in the treatment of depres-
sion. The size of the boxes is proportional to the sample size.
The overall combined effect size is indicated by a diamond.
See Burt et al
104 for a review of the individual studies included
in the meta-analysis. 
Reproduced from reference 104: Burt T, Lisanby SH, Sackeim HA.
Neuropsychiatric applications of transcranial magnetic stimulation: a
meta analysis. Int J Neuropsychopharmacol. 2002;5:73-103. Copyright
© Cambridge University Press, 2002.
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              Combined (23)antidepressant effect in nonpsychotic major depressive
disorder,
116,117 but ECT has been found to be superior for
psychotic major depressive disorder.
117
Older age, treatment refractoriness, and psychotic
depression have been found to be negative predictors of
depression improvement with TMS.
115,119 Pretreatment
cerebral metabolism has been found to correlate with
antidepressant response to TMS
120;for example,hypome-
tabolism in the temporal lobes,cerebellum,anterior and
occipital cingulate regions has been associated with
improvement with fast rTMS while hypermetabolism
had been associated with improvement with slow
rTMS.
121
Some preliminary data suggest that TMS might be used
as a maintenance treatment for patients with depres-
sion.
122TMS has recently been shown to accelerate the
antidepressant effect of amitriptyline
123;previously it had
not been shown that concomitant use of antidepressant
medication influences the therapeutic effect of TMS.
110
Course duration of more than 10 days had been found to
be associated with a better antidepressant effect,
124 and
treatment for at least 4 weeks is considered to have clin-
ically meaningful benefits.
125 More intense magnetic
pulses (100% to 110% of motor threshold) have been
shown to be more effective that less intense pulses (80%
to 90% of motor threshold), and more pulses per day
(1200 to 1600 pulses per day) has been shown to be more
effective than fewer pulses per day (800 to 1000 pulses
per day).
124 High-frequency rTMS has not been shown to
be superior to low-frequency rTMS.
126,127 Low-frequency
rTMS is considered safer,and its use is recommended.
110
Adverse effects
TMS is considered a safe procedure, without clinically
significant changes in cognitive parameters,
128 hearing,or
hormone levels.
129The major risk of TMS is seizure induc-
tion, associated primarily with high-frequency rTMS.
Since the introduction of standards of safety for the
administration of TMS,
105 no TMS-induced seizure has
been reported.Other adverse effects include headaches,
scalp facial muscle twitching, and mild tinnitus, which
usually respond to analgesics.
Mechanism of action
TMS causes functional changes in the brain.Performing
magnetic resonance imaging (MRI) scans before and
after rTMS in depressed patients did not reveal any
structural difference,and volumetric analysis of the pre-
frontal lobe showed no changes.
130 However,many stud-
ies have demonstrated that TMS changes cortical
excitability
131 and that higher intensity TMS causes
greater activation than lower intensity TMS.
132 These
changes in cortical excitability occur at the primary site
of excitation (neuronal activation in sites under the coil)
as well as in distant brain areas.
133
Clinical improvement in depression using rTMS has been
associated with changes in cerebral blood flow in the pre-
frontal and paralimbic areas.
134 SPECT scans that were
obtained from patients with major depression resistant
to medication before and after 10 days of rTMS,demon-
strated that treatment responders had significantly less
pretreatment blood flow in the left amygdala compared
with nonresponders, and only the responders demon-
strated two patterns of change in regional blood flow
with treatment:a reduction in orbitofrontal blood flow
and/or a reduction in anterior cingulate blood flow.
135
Using animal models,rTMS-induced changes in neuro-
transmitters have been found.Some of these changes are
similar to the effect of other antidepressant therapy (such
as ECS).
136-138 For example, a single rTMS session was
associated with increased hippocampal dopamine and
serotonin.
136 Chronic rTMS was associated with upregu-
lation of β-adrenergic and serotonin receptors in the
frontal cortex, with downregulation of β-adrenergic
receptors in the striatum
137 and with subsensitivity of
presynaptic serotonergic autoreceptors,an effect that is
shared with antidepressant drugs.
132
rTMS has been shown to have some metabolic and neu-
roendocrine effects. Using proton magnetic resonance
spectroscopy following high-frequency rTMS in healthy
volunteers,it was demonstrated that rTMS affects cortical
glutamate/glutamine levels,both close to the stimulation
site (left dorsolateral prefrontal cortex) and in remote
brain regions (right dorsolateral prefrontal cortex,left cin-
gulate cortex).These data indicate that rTMS may act via
stimulation of glutamatergic prefrontal neurons.
139 rTMS
has been shown to increase thyroid-stimulating hormone
(TSH) in healthy individuals
140 and in patients with major
depression.
141 In patients with depression who remitted
after rTMS,reversal of dexamethasone suppression test
(DST) abnormality was demonstrated.
142
rTMS has recently been associated with neuroplasticity
and neurogenesis. For example, rTMS can modulate
astroglial gene expression;following rTMS,an increased
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ribonucleic acid (mRNA) was found in the hippocampal
dentate gyrus.
143 rTMS can also increase immediate early
gene expression,such as c-fos and c-jun.
144,145
It had been suggested that a change in local blood-brain
barrier settings,allowing passage of peripheral substances
directly into brain parenchyma,may be the mechanism
of TMS.However,it has recently been demonstrated that
TMS does not result in leakage of the blood-brain bar-
rier in patients with depression.
146
Magnetic seizure therapy 
Magnetic seizure therapy (MST) is a novel brain stimu-
lation method that uses transcranial magnetic stimula-
tion at convulsive parameters in order to induce thera-
peutic seizures under general anesthesia, in the same
setting used for ECT.
147After its introduction in 2000,a
few case reports described successful treatment of
patients suffering from major depression using MST
110,148
but it is not yet established that MST has antidepressant
efficacy.In a recent study by Lisanby et al,
110 10 patients
with major depression received two treatments with
MST followed by two treatments with ECT,in random-
ized order. MST seizures were found to have shorter
duration,lower ictal EEG amplitude,and less postictal
suppression than ECT seizures.
149 MST might cause fewer
cognitive side effects than ECT, by inducing more
focused seizures and sparing cortical regions associated
with memory loss. In a nonhuman primate model
(Rhesus macaque monkeys),MST was shown to result in
a more favorable acute cognitive side-effect profile than
ECT with regard to long-term memory of a constant tar-
get,short-term memory of a variable target,and recall of
previously learned three-item lists.
150,151 Preliminary clin-
ical data are seen as suggesting that MST has antide-
pressant properties and fewer cognitive side effects than
ECT.
152 For example,patients recover orientation more
quickly and have fewer attention difficulties or less ret-




Deep brain stimulation (DBS) was introduced in the late
1980s by Benabid and colleagues, for the treatment of
movement disorders.
153 Their original assumption was
that chronic high-frequency stimulation of the brain
areas might be similar to surgical ablation of these
areas.
154 For example,thalamic stimulation for the treat-
ment of intractable tremor was found to have clinical
benefits similar to those achieved by surgical thalamo-
tomy
155 and stimulation of the subthalamic nucleus or
globus pallidus internus for the treatment of Parkinson's
disease could replace the traditional pallidotomy.
156 Over
the last decade,DBS has become a popular treatment for
movement disorders such as Parkinson's disease and
essential tremor.
157 During the last few years, DBS has
been suggested as a treatment for psychiatric disorders,
such as depression




The surgical procedure for the implantation of DBS elec-
trodes is based on stereotactic techniques that include
imaging modalities,physiological mapping,and surgical
navigation computers.
160A stereotactic frame is fixed to
the patient's head,and preoperative magnetic resonance
images are obtained.Under local anesthesia,a burr hole
is drilled, the underlying dura mater is opened, and
microelectrodes are inserted using MRI guidance.The
electrode location is confirmed by postoperative MRI.
Right and left quadripolar electrodes are implanted.The
electrodes remain externalized for a week for clinical
testing,and then are connected to a pulse generator that
is implanted in the infraclavicular region.The frequency,
intensity, and pulse width of the stimulation are pro-
grammable, within safety limits.The physician sets the
stimulus parameters,and the patient might also alter a
few parameters by him- or herself. Stimulation can be
programmed to continuous or intermittent firing,or to
on and off cycles during fixed time intervals. DBS is
reversible, and the stimulation parameters can be
changed according to patient's symptoms or disease pro-
gression.
DBS in the treatment of major depression
To date,a few case reports suggest that DBS might be a
useful treatment for refractory depression. Recently,
Mayberg and colleagues
158 found that DBS of the white
matter tracts adjacent to the subgenual cingulate gyrus
was associated with improvement in depressive symp-
toms in 6 patients with refractory depression.By 1 and 6
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response,respectively.Remission was achieved by three
patients after 6 months.
158 Deep brain stimulation of the
ventral caudate nucleus improved anxiety, depressive,
and compulsive symptoms in one patient who suffered
from resistant obsessive-compulsive disorder and resis-
tant major depression.
159 Deep-brain stimulation of the
inferior thalamic peduncle improved depressive symp-
toms in one patient suffering from recurrent unipolar
depression and borderline personality disorder.
161
Adverse effects
Major side effects of DBS are seizure (1% to 3%),hem-
orrhage (1% to 5%), infection (2% to 25%, usually
superficial infections but rarely cerebritis or brain
abscess) and hardware-related complications (about
25%) that include fracture of leads,disconnection,lead
movement, and malfunction.
162,163 Stimulation-induced
adverse effects such as parasthesia,muscle contraction,




Investigating the mechanism of deep brain stimulation
reveals a basic paradox:the clinical effect of deep brain
stimulation, which is usually regarded as a method of
activating neurons,is similar to the traditional ablation
of specific brain areas.
165 Studies aimed at resolving this
paradox have led to the development of four major the-
ories regarding the mechanism of action of DBS.The first
theory suggests that irregular activity in neurons con-
verging with other neurons can result in a loss of infor-
mation transfer and thus cause clinical pathology.The
therapeutic effect of DBS may be due to its driving neu-
rons at regular frequencies, and thus modulating the
pathological network activity and increasing neuronal
activity in the output nuclei.
166 Many studies using func-
tional imaging demonstrate increased cortical activity
during DBS treatment. For example, activation of the
thalamus and basal ganglia was demonstrated by fMRI
studies
167 and activation of motor cortex and supplemen-
tary motor area was demonstrated by PET studies.
168,169
The second theory suggests that excitation of axon ter-
minals near the stimulation electrode releases inhibitory
factors that cause synaptic inhibition of the neuron.
170The
third theory suggests that high-frequency tetanus pro-
duces a blockade of the spontaneous activities of neurons
as a result of a strong depression of intrinsic voltage-
gated currents,
171 and thus DBS causes a depolarization
blockade.Theories of synaptic inhibition and depolar-
ization blockade are both supported by the decreased
recordings of somatic activity in the stimulated nuclei.
The fourth theory suggests that the stimulation causes
synaptic depression by transmitter depletion.
172,173
Although depression is probably a disorder of multiple
brain areas,neuronal pathways,neurotransmitters,and
genomic systems,DBS requires stimulation of a single
brain area.Many studies indicate that the limbic-cortical
pathways and specifically the subgenual cingulate (Cg25)
are involved in acute sadness and in the antidepressant
effect of medications,electroconvulsive therapy,and tran-
scranial magnetic stimulation.
174-176 Therefore, this area
was first tested by Mayberg and colleagues for the effi-
cacy of DBS as a treatment for major depression. By
using pretreatment and post-treatment PET scans,it was
demonstrated that the cerebral blood flow abnormalities
related to depression,such as decreased blood flow in the
prefrontal area and increased blood flow in the subgen-





The vagus nerve, the longest of the cranial nerves, is a
mixed nerve, with 80% of the fibers carrying afferent
information (to the brain) and 20% of the fibers carry-
ing efferent information (from the brain).Afferent sen-
sory fibers within the vagus nerve terminate in the
nucleus tractus solitarius (NTS),which innervates many
brain regions that are related to psychiatric disorders (for
example,locus ceruleus,amygdala,and hypothalamus).
The potential of vagal nerve stimulation to influence cen-
tral nervous system function was demonstrated long
before its use as a therapeutic intervention was consid-
ered.
177,178 During the 1980s,Zabara showed that VNS has
an anticonvulsant action in dogs
179 and during the 1990s
VNS became a treatment modality for epilepsy in
humans.
180,181 In 2000,VNS was found to be associated
with mood improvements in patients with epilepsy.
182,183
VNS has also been demonstrated to affect specific brain
areas including the limbic system
184 and to alter concen-
tration of monoamines within the central nervous system
ECT and brain stimulation - Eitan and Lerer Dialogues in Clinical Neuroscience - Vol 8 . No.2 . 2006
251(such as serotonin,norepinephrine,GABA,and gluta-
mate).
185,186These clinical and laboratory findings,together
with the efficacy of anticonvulsant medications as a treat-
ment for depressive episodes,has led to the hypothesis




VNS is performed in humans by stimulation of the left
cervical vagus nerve using a subcutaneous generator that
sends an electrical signal to the nerve.
188The generator is
implanted into the left chest wall.Bipolar electrodes are
wrapped around the left vagus in the neck through a spe-
cial incision, and tunneled under the skin toward the
chest.
189The stimulation parameters that can be adjusted
by the physician include current intensity,pulse width,
frequency, and duration of the on and off periods.The
generator is designed to shut off in the presence of a
magnetic field,and the patient is given a magnet that can
turn off the stimulation when held over the generator.
VNS in the treatment of major depression
VNS was recently demonstrated to have an antidepres-
sant effect in a rat model,significantly better than sham
treatment,and similar to other antidepressant treatments
(desipramine or ECS).
190 During the past 5 years,
Sackeim,Rush,and colleagues have published results of
open and randomized controlled studies of VNS in the
treatment of major depression.A preliminary open study
of VNS in 60 patients with treatment-resistant nonpsy-
chotic major depressive episode revealed a response rate
of 30% to 38% by 10 weeks of treatment.
191A 2-year fol-
low-up of this open study found a response rate of 40%
to 44% after 1 year and 42% after 2 years,and a remis-
sion rate of 27% after 1 year and 22% after 2 years.
192,193
A randomized controlled study of VNS in over 200
patients with treatment-resistant, nonpsychotic, major
depressive episode showed that acute treatment (10
weeks) yielded a response rate of 15% that was similar
to the response rate with sham treatment (10%).
194After
the acute treatment,all patients (VNS and sham groups)
received long-term treatment with VNS for another 12
months.This was associated with a response rate of 27%
and a remission rate of 16%.
195The response rate in the
group of patients who were receiving VNS plus medica-
tion or ECT for a year (27%) was significantly better
than the response rate of a similar but nonrandomized
group of patients with treatment-resistant depression
who were receiving only medication or ECT for a year
(response rate was only 13%).
196
Adverse effects
The most common side effects of VNS are voice alter-
ation or hoarseness (55%),coughing (17%),shortness of
breath (15%), headache (22%), neck pain (17%), dys-
phagia (20%), and pain (15%). Although most side
effects usually resolve within a few weeks, voice alter-
ation and dyspnea might persist for long periods.




VNS most probably alters synaptic activities at vagal
afferent terminations,stimulates deep brain areas,and
thus modulates antidepressant neuronal circuits in mul-
tiple limbic system structures. Brain imaging studies
reveal some of these suspected brain changes.PET mea-
surements of cerebral blood flow in 10 patients with
epilepsy before and during acute VNS treatment (both
low- and high-stimulation VNS) demonstrated increased
blood flow in the rostral,dorsal-central medulla,the right
postcentral gyrus,bilaterally in the hypothalami,thalami,
and insular cortices,and in the cerebellar hemispheres
inferiorly.Decreased blood flow was demonstrated bilat-
erally in hippocampus,amygdala,and posterior cingulate
gyri.
184 Similar changes in cerebral blood flow were also
demonstrated during prolonged VNS treatment.
197 Some
of these findings share features with changes of regional
cerebral blood flow previously associated with the
administration of antidepressant drugs (such as selective
serotonin reuptake inhibitors).
198 fMRI studies confirmed
that VNS induces changes in the orbitofrontal and pari-
eto-occipital cortex bilaterally,left temporal cortex,hypo-
thalamus,and left amygdala
199 and suggested that VNS at
different frequencies has frequency or dose-dependent
modulatory effects on brain activities.
200
In addition, VNS is associated with neurobiological
changes that are related to the pathogenesis of depres-
sion:
•VNS has been found to alter concentrations of neuro-
transmitters that are probably involved in the mecha-
nism of depression.VNS was associated with increased
Clinical research
252GABA,5-hydroxyindoleacetic acid and homovanillic
acid levels and decreased aspartate and glutamate 
levels.
186,201
•VNS was associated with neuroimmunological changes
such as a marked peripheral increase in pro- and anti-
inflammatory circulating cytokines,such as IL-6,TNF-α,
and TGF-β.
202
•A preliminary study suggests that VNS treatment
changes the hypothalamic-pituitary-adrenal (HPA) axis
stress system.In patients with chronic depression,cor-
ticotrophin-releasing hormone (CRH) challenge causes
increased adrenocorticotrophic hormone (ACTH) lev-
els.VNS treatment of depressed patients reversed this
abnormally increased ACTH response to CRH chal-
lenge.
203
•VNS treatment was associated with improvement in
abnormal sleep architecture in patients with depression.
204
Conclusions
Several novel nonpharmacological,somatic treatments
for major depression have been reviewed.All are based
on the principle of brain stimulation.Other than ECT,
TMS is the only one of these treatments that is relatively
widely used.The clinical efficacy of TMS is not conclu-
sively established,and its precise therapeutic niche still
needs to be defined.TMS does not appear to be a viable
alternative to ECT for treatment-refractory,depressed
patients.There is very great interest in the potential of
MST.If magnetically induced seizures are effective clin-
ically but induce fewer cognitive adverse effects than
ECT,this would be a very great advantage.Early studies
suggest that this may be so,but the field is still at a very
early stage of development and further research is
needed.The last two modalities discussed,DBS and VNS,
are both characterized by high cost and the potential for
troublesome adverse effects.Both entail surgical proce-
dures.Their indication,if efficacy is established and tech-
nical issues are resolved, would be for highly resistant
patients where the complexity of the treatment and its
expense are warranted. Some trials of VNS have been
conducted.Their results suggest equivocal efficacy in the
short term, but longer-term effects might be more
promising.The clinical application of DBS is still at very
early stage.
In practical terms ECT remains the only widely available,
nonpharmacological, somatic treatment of depression
that is effective,safe,and relatively inexpensive.This is
likely to remain the situation in the short term. In the
longer term,other approaches to brain stimulation may
become clinically viable and eventually replace ECT.
Such a projection must be made with due caution.The
epitaph of ECT has been written repeatedly over the
past 50 years.Nevertheless,it remains one of the longest-
standing, continuously used treatments in medicine.
Research efforts over the next decade in the field of
brain stimulation will be crucial in establishing how long
ECT will continue to occupy this unique position. ❏
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Tratamientos somáticos no farmacológicos de
la depresión: terapia electroconvulsiva y 
nuevas modalidades de estimulación cerebral
Hasta hace muy poco tiempo una revisión de los
tratamientos somáticos, no farmacológicos de los
trastornos psiquiátricos habría incluido sólo la tera-
pia electrocovulsiva (TEC). Esta situación está cam-
biando significativamente en la actualidad. Aunque
la TEC permanece como la única modalidad de
amplio uso clínico, existen nuevas técnicas que
están en investigación. La principal indicación en el
ámbito psiquiátrico es el tratamiento de la depre-
sión mayor, pero también se están estudiando otras
aplicaciones. Todos los nuevos tratamientos incor-
poran la estimulación cerebral, la que se obtiene a
través de diferentes métodos tecnológicos. El tra-
tamiento más cercano al límite de la aceptación clí-
nica es la estimulación magnética transcraneal
(EMT). Aunque la EMT es segura y relativamente
fácil de administrar, su eficacia aun no ha sido defi-
nitivamente establecida. Otras modalidades, en
diversas etapas de investigación, incluyen la terapia
magnética convulsiva (TMC), la estimulación cere-
bral profunda (ECP) y la estimulación del nervio
vago (ENV). Se revisa brevemente el desarrollo y los
aspectos técnicos de estos tratamientos, su poten-
cial papel en el tratamiento de la depresión, los
efectos adversos y los mecanismos de acción. Se
revisa en mayor extensión la TEC por ser la única de
estas modalidades terapéuticas que se utiliza
ampliamente en clínica. Aunque ha transcurrido
más de medio siglo desde que la TEC fue introdu-
cida por primera vez, ésta continúa siendo el trata-
miento más efectivo para la depresión mayor, con
eficacia en pacientes refractarios a los fármacos
antidepresivos y con un aceptable perfil de seguri-
dad. Aunque las nuevas técnicas de estimulación
cerebral revisadas acá parecen promisorias, reque-
rirán de un mayor desarrollo a futuro antes de que
alcancen aceptación clínica.  
Traitements somatiques, non pharmacolo-
giques de la dépression : électrochoc et 
nouvelles modalités de stimulation cérébrale
Il y a peu de temps encore, une analyse des traite-
ments somatiques non pharmacologiques des
troubles psychiatriques n’aurait compris que l’élec-
trochoc. Cette situation est en train de changer
notablement. Bien que l’électrochoc reste la seule
modalité en pratique clinique courante, plusieurs
nouvelles techniques sont en expérimentation. Leur
indication principale dans le contexte psychiatrique
est le traitement de la dépression majeure, mais
d’autres applications sont en cours d’étude. Tous les
nouveaux traitements font intervenir la stimulation
cérébrale, réalisée par différentes techniques. Le
traitement le plus proche du seuil d’acceptabilité
clinique est la stimulation magnétique transcrâ-
nienne (SMT). Bien que la SMT soit sûre et relative-
ment facile à administrer, son efficacité doit encore
être définitivement établie. D’autres modalités, à
différents stades de recherche, comprennent le trai-
tement d’attaque magnétique (TAM), la stimulation
cérébrale profonde (SCP) et la stimulation du nerf
vagal (SNV). Nous analysons brièvement le déve-
loppement et les aspects techniques de ces traite-
ments, leur rôle potentiel dans le traitement de la
dépression majeure, leurs effets indésirables et leur
mécanisme d’action reconnu. Une attention plus
importante est portée à l’électrochoc, car c’est le
seul de ces traitements qui est utilisé en pratique
clinique courante. Bien que l’introduction de l’élec-
trochoc remonte à plus d’un demi siècle, il reste le
traitement le plus efficace de la dépression
majeure, efficace chez les patients résistants aux
antidépresseurs et doté d’un profil de sécurité
acceptable. Bien que très prometteuses, les nou-
velles techniques de stimulation cérébrale analysées
ici devront faire l’objet d’un développement ulté-
rieur avant d’obtenir une acceptabilité clinique.
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